Navigation Links
ViroPharma to Release 2008 First Quarter Financial Results on April 30, 2008
Date:4/14/2008

- Conference Call to Discuss Results to Be Held at 9:00 A.M. -

EXTON, Pa., April 14 /PRNewswire-FirstCall/ -- ViroPharma Incorporated's (Nasdaq: VPHM) first quarter financial results for 2008 are expected to be released on Wednesday, April 30, 2008 before the open of the U.S. financial markets.

The company will host a conference call and live audio webcast at 9:00 a.m. Eastern Time on the same day. During the conference call, ViroPharma management will discuss the 2008 first quarter financial results and other business.

The press release and the live webcast of the conference call will be accessible via ViroPharma's corporate website at http://www.viropharma.com. An audio archive will be available at the same address until May 14, 2008. To participate in the conference call, please dial (877) 366-0713 (domestic) and (302) 607-2000 (international). After placing the call, please tell the operator you wish to join the ViroPharma investor conference call.

About ViroPharma Incorporated

ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin- resistant strains (for prescribing information, please download the package insert at http://www.viropharma.com/Products.aspx). ViroPharma currently focuses its d
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. ViroPharma To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
2. ViroPharma to Present at the Natixis Bleichroeder Conference
3. ViroPharma to Present at Three Upcoming Healthcare Conferences
4. New Research for Mechanical Support Devices in Pediatrics to Be Released at International Heart and Lung Transplant Meeting
5. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
6. Immunosyn Releases Wound Healing Photographs From the First Phase Proof of Concept Trial in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019
7. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
8. DATATRAK(TM) Takes Clinical Trial Solutions to the Next Level With the Release of 5.0
9. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
10. Keppra XR(TM) Extended-Release Tablets Filed with the FDA
11. UCB Announces Positive Phase III Trial Results for Keppra XR(TM) (levetiracetam) Extended-Release Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... July 31, 2014  ResMed Inc. (NYSE: RMD ... the fiscal year ended June 30, 2014.  Revenue for the ... June 30, 2013 (a 1 percent decrease on a constant ... 20 percent compared to the quarter ended June 30, 2013. ... increase of 22 percent compared to the quarter ended June ...
(Date:7/31/2014)... 2014 Nektar Therapeutics (Nasdaq: NKTR ) ... June 30, 2014. Cash and investments in ... compared to $309.1 million at March 31, 2014."The second half ... we look forward to significant milestones for a number of ... Chief Executive Officer of Nektar. "The first of these is ...
(Date:7/31/2014)... , July 31, 2014  Decision ... changes brought about by the Affordable Care ... and prescribing of pharmaceutical therapies. The ACA ... beneficiaries through new regulations and expanded access ... in the health exchanges—state-based marketplaces set up ...
Breaking Medicine Technology:RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 4RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 5RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 6RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 7RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 8RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 9RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 10RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 11RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 12RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 13Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 2Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 3Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 4Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 5Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 6Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 7Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 8Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 9Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 10Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 11Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 12Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 13Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 14Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 2Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 3Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 4
(Date:8/1/2014)... 2014 According to new market ... (Asia-Pacific, North America, Europe, & ROW), by Vehicle ... Type (Gasoline & Diesel), by After-Treatment Device (DPF, ... & Forecasts to 2019", defines and segments the ... of major countries in all the regions, and ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 The North ... endpoint security solutions market in North America with analysis ... grow from around $3.53 billion in 2014 to $4.77 ... 2014 to 2019. , Browse through the TOC of ... an idea of the in-depth analysis provided. It also ...
(Date:8/1/2014)... 2014 For years, proponents have praised ... study conducted by the Ohio State University, ... behind in terms of their health and development, raising ... best for their baby. So does this new research ... Steven Shapiro , chair of Pediatrics at Abington Memorial ...
(Date:8/1/2014)... Over the past five years, ... technologies that have enabled cosmetic dentists to provide ... Moreover, the burgeoning elderly population has stimulated demand ... Due to long-term use of medications, which may ... dental fillings, veneers and implants. As more elderly ...
(Date:8/1/2014)... YORK, NY August 1, 2014 The ... trials and first report investigations that will be ... 2014 scientific symposium. TCT, the world,s premier educational ... place September 13 17, 2014 at the ... , Clinical research data presented at TCT often ...
Breaking Medicine News(10 mins):Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 2Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 3Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 4Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 2Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 3Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 4Health News:Despite Recent Study, Abington Health Expert Encourages Breastfeeding 2Health News:Despite Recent Study, Abington Health Expert Encourages Breastfeeding 3Health News:Cosmetic Dentists in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Cosmetic Dentists in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:CRF announces late-breaking trials and first report investigations for TCT 2014 2Health News:CRF announces late-breaking trials and first report investigations for TCT 2014 3Health News:CRF announces late-breaking trials and first report investigations for TCT 2014 4
... and WINSTON-SALEM, N.C., March 27 Prince William ... Carolina-based Novant Health, both regional not-for-profit health systems, ... intent to merge. The partnership will provide ... to western Prince William County. "We chose to ...
... covers the entire spectrum - from medical imaging, ... March 27 /PRNewswire/ -- Siemens Healthcare ( ... commitment to excellence "From Prevention to Follow-up" at ... College of Cardiology (ACC), March 29-31 in Orlando, ...
... team of scientists at Emory University School of Medicine ... inflammatory signals in the blood. The finding could lead ... antioxidants in the diet and for reducing the impact ... to intravenous or tube feeding. , The results are ...
... Analysis shows most documents require reading skills beyond those ... -- This one should come as no surprise to ... that outlines your expectations for medical care, is usually ... that you need college-level reading skills to understand ...
... Beauty Show, March 28-30 in Chicago, is dedicated ... doing so, the Show raises serious and decades ... salons. Salon products are generally dispensed from bulk ... is the cumulative contamination of air, particularly in ...
... 27 Cord Blood America, Inc. (OTC Bulletin Board: ... ( http://www.cordblood-america.com ) focused on ... families nationwide and internationally, said today it strongly supports ... U.S. House of Representatives.The legislation will provide tax incentives ...
Cached Medicine News:Health News:Prince William Health System and Novant Health Agree on Partnership to Expand Quality Healthcare in Northern Virginia 2Health News:Prince William Health System and Novant Health Agree on Partnership to Expand Quality Healthcare in Northern Virginia 3Health News:Siemens Highlights Cardiology Excellence from Prevention to Follow-up at ACC 2009 2Health News:Siemens Highlights Cardiology Excellence from Prevention to Follow-up at ACC 2009 3Health News:Siemens Highlights Cardiology Excellence from Prevention to Follow-up at ACC 2009 4Health News:Siemens Highlights Cardiology Excellence from Prevention to Follow-up at ACC 2009 5Health News:Siemens Highlights Cardiology Excellence from Prevention to Follow-up at ACC 2009 6Health News:Siemens Highlights Cardiology Excellence from Prevention to Follow-up at ACC 2009 7Health News:Targeting oxidized cysteine through diet could reduce inflammation and lower disease risk 2Health News:Patients' Bill of Rights Too Tough to Read 2Health News:Patients' Bill of Rights Too Tough to Read 3Health News:America's Beauty Show Challenges Toxic Salons 2Health News:America's Beauty Show Challenges Toxic Salons 3Health News:Cord Blood America Applauds Congressional Effort Supporting Cord Blood Storage 2
CapSureSP Novus 5594 is a J-shaped, endocardial, tined pacing lead. provide the stable, low pacing thresholds and large sensing potentials already proven with CapSure SP steroid-eluting leads but wi...
The Guidant Fineline II Sterox Atrial J is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications....
The Guidant Fineline II Sterox is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications....
The electrically active helix of CapSureFix Novus lead is designed to extend easily for active fixation and retract for venous passage....
Medicine Products: